Although effective anti-malarial drugs are on the market, the disease remains a threat to people living in endemic areas who have no proper and prompt access to effective drugs. Access to pharmacies and health facilities, as well as drug costs, are major obstacles. Médecins Sans Frontières estimates that the cost of treating a<unk> -infected person in an endemic country was between US$0.25 and $2.40 per dose in 2002.
Malaria cost-effectiveness of therapy
Leprosy cost-effectiveness of therapy
Rubella cost-effectiveness of therapy
Tuberculosis cost-effectiveness of therapy
Tetanus cost-effectiveness of therapy
Listeriosis cost-effectiveness of therapy
HIV AIDS cost-effectiveness of therapy
Influenza cost-effectiveness of therapy